A Phase 4 interventional study of Clareon PanOptix and Clareon PanOptix PRO in Cataract, sponsored by Berkeley Eye Center. Recruiting at 2 sites in United States. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Berkeley Eye Center · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 456 studies in Cataract with a site in United States — 49 open to participants now, 56 under way, 4 of them phase 3. Cataract · United States.
Among the 456 studies in Cataract with a site in United States, this one is the 66th largest by planned enrollment of the 322 interventional ones that give a count, is one of 24 that started in 2025, is one of 86 in phase 4, reaches primary completion later than 34 of the 54 other live ones, and was the 409th registered.
1,632 studies on the registry are indexed under Cataract; 235 are open to participants now.
Browse Cataract studies →49 of the 456 studies in Cataract with a site in United States are open now. Recruiting first, the newest first:
Cleveland Eye Clinic · Sites in United States
Ages 50–75
Eric Rosenberg · Sites in United States
Ages 18–90
The Eye Institute of West Florida · Sites in United States
Ages 40+
Gainesville Eye Associates · Sites in United States
Ages 18+
Laser Defined Vision · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 142 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.
This study: 40 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
456 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 25 · Phase 3 59 · Phase 4 86
First in 1987; this study’s year is marked. 24 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 320 is above the median of 79 across 1,094 interventional studies indexed under Cataract.
Median enrollment 100 across the 322 interventional studies, 61 across the 128 observational. Of the 365 that completed or were terminated, 177 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
239 of 456 have an industry lead sponsor. The 10 most frequent:
Berkeley Eye Center is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Berkeley Eye Center has 3 studies filed under Cataract — fewer than ten, so there is no comparison to draw.
21 of the studies in Cataract with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07898917Gainesville Eye AssociatesPureSee/Odyssey Mix-and-Match IOL | 2026-12 |
| NCT07928986Cleveland Eye ClinicA Multi Center Evaluation of TearCare on Surgical Measurements Before Cataract Surgery | 2026-12 |
| NCT07260695Center For SightOdyssey Evaluation in Post LASIK Patients | 2026-12-18 |
| NCT03713268Duke UniversityIntraoperative OCT Guidance of Intraocular Surgery II | 2026-12-31 |
| NCT07715591University of California, Los AngelesRandomized Controlled Trial of the STEIN Protocol: A Neuroplastic Pain Education and Guided Breathing Intervention During Awake Cataract Surgery | 2026-12-31 |
Add all 21 to your calendar (.ics) → With an account.
Among the 456 studies in Cataract with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Prospective, randomized, multicenter, multi-arm, subject and vision-assessor-masked, two stage study with Stage 1 as a three-arm initial enrollment period, followed by Stage 2 as a head-to-head study refined based on the Stage 1 data.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Clareon PanOptix
Drug: Clareon PanOptix PRO
Drug: Mix-and-Match PanOptix/Vivity
Bilateral Clareon PanOptix IOL implantation
Bilateral Clareon PanOptix PRO IOL implantation
Clareon PanOptix Pro in the non-dominant eye and Clareon Vivity in the dominant eye
Binocular photopic CDVA (corrected distance visual acuity)
Time frame: 3 months postoperatively
Binocular photopic DCIVA (distance corrected intermediate visual acuity) and DCNVA (distance corrected near visual acuity)
Time frame: 3 months postoperatively
Binocular photopic uncorrected visual acuity at distance (UDVA), intermediate (UIVA), and near (UNVA)
Time frame: 3 months postoperatively
Binocular photopic small letter contrast sensitivity at 66 cm and 100 cm with refractive distance correction (20/32 line)
Time frame: 3 months postoperatively
Binocular mesopic high contrast distance corrected visual acuity at distance (CDVA), intermediate (DCIVA), and near (DCNVA).
Time frame: 3 months postoperatively
Binocular photopic distance corrected defocus curve
Obtained by varying the vergence of the stimulus from -3.0 D to +1.0 D in steps of 0.5 D with the best correction for distance vision.
Time frame: 3 months postoperatively
Monocular photopic distance corrected defocus curves
Obtained by varying the vergence of the stimulus from -3.0 D to +1.0 D in steps of 0.5 D with the best correction for distance vision.
Time frame: 3 months postoperatively
Binocular mesopic distance corrected contrast sensitivity with and without glare (1.5, 3, 6 & 12 cpd)
Time frame: 3 months postoperatively
Refractive outcomes
Mean residual manifest refraction spherical equivalent (MRSE) and residual astigmatism.
Time frame: 3 months postoperatively
Pupil size
Under both photopic and mesopic conditions.
Time frame: 3 months postoperatively
Patient-reported outcomes using a questionnaire about visual disturbances (QUVID)
Time frame: 3 months postoperatively
Patient-reported outcomes using a questionnaire about IOL satisfaction (IOLSAT)
Time frame: 3 months postoperatively
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Apr 2027, 25 months after the start.
Of 39 non-industry phase 4 interventional studies under Cataract, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 39. This study's planned 25 months is above that.
Counting every sponsor, half of 46 studies reached it within 20 months; a quarter within 11 and three quarters within 34.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Apr 2026 → Apr 2027 and completion Apr 2026 → Apr 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Berkeley Eye Center